Apply to join
Member Sign In
Member Sign Out
Cell & Gene Therapy
Apply to Join
Cell & Gene Therapy
Avance Biosciences expands cell, gene therapy research capabilities
Contract research organization Avance Biosciences is expanding its Houston facility to meet growing demand for cell-based manufacturing.
Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and chimeric antigen receptor NK cells derived from induced pluripotent stem cells.
Dyno publishes data on optimized AAV capsids for gene therapy
Dyno Therapeutics recently highlighted an article in
that demonstrates the use of its artificial intelligence platform to generate diverse adeno-associated virus (AAV) capsids with functional variants capable of evading the immune system.
Cellaria, BioLamina partner on new cell culture models
Cellaria and BioLamina have announced that they plan to collaborate on developing new cell culture models for cancer research, tissue modeling, drug screening, and research in basic and regenerative medicine.
Startup Ensoma launches with gene therapy vector platform
A new genomic medicine startup called Ensoma made its corporate debut this week, raising $70 million in financing and entering into a strategic collaboration with Takeda Pharmaceutical.
Rentschler sets up cell and gene therapy center of excellence in U.K.
Contract development and manufacturing organization Rentschler Biopharma has announced that it is establishing a center for excellence for cell and gene therapy. The center will be located in Stevenage, U.K.
Notch nabs $85M in funding for stem cell-based cell therapies
Notch Therapeutics has closed $85 million in series A financing to continue the development of its portfolio of induced pluripotent stem cell-derived cell therapies for cancer, as well as its proprietary engineered Thymic Niche platform.
Researchers use modified CRISPR tool to manipulate the epigenome
Bioengineers have developed a new way to engineer the human epigenome (chemical changes in the DNA) using a modified CRISPR-Cas9 system to target and activate proteins in the chromosome. This research, published in
on February 9, expands on synthetic genome tools.
Global Genes produces series on gene therapy, editing
Rare disease patient advocacy organization Global Genes will publish a multimedia series about advances in gene therapy and gene editing technology throughout 2021.
Bio-Path gets patent for nucleic acid drug platform
The U.S. Patent and Trademark Office has granted a patent to Bio-Path Holdings for its nucleic acid drug platform, expanding protections for the company's DNAbilize technology.
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Tweets by @ScienceBoard